

QIBA PET Amyloid Biomarker Committee

12 February 2016 at 9 AM CT

Call Summary

In attendance:

<i>Eric Perlman, MD (co-chair)</i>	Adriaan Lammertsma, PhD	Charles Smith, MSCS	RSNA Joe Koudelik
Christopher Buckley, PhD	Martin Lodge, PhD	Rathan Subramaniam, MD, PhD, MPH	Julie Lisiecki
Santiago (Santi) Bullich, PhD	Dawn Matthews, MS, MBA	John Sunderland, PhD	
Paul Kinahan, PhD	Nancy Obuchowski, PhD	Jean-Luc Vanderheyden, PhD	
Gregory Klein, PhD	Sara Sheikbahaei, PhD		

Literature Analysis / Claim Language (Drs. Obuchowski / Subramaniam)

- A study using fluorine-18-labeled amyloid imaging agents including 23 Alzheimer's disease patients was reviewed
- [Guidelines for assigning values for claim statements](#) were discussed
- Items in progress:
 - Confidence intervals with plausible values for the repeatability coefficient
 - Determine scanning component error re SUV measurements; establishing SUV thresholds needed
 - Clinical requirements as related to clinical needs for quantitative imaging biomarker performance

Phantom / DRO Update (Drs. Sunderland / Kinahan)

- The phantom is being used to solve a scanning error by segmenting out the imaging aspect for detailed analysis
- Goal is to achieve a grey to white matter contrast that is appropriate for amyloid tracers, avoiding void volumes
- The team is starting with negative cases where white matter and the brain stem are used
- It was noted that it is vitally important that tracer manufacturers provide input
 - Details will be used to update the Profile more extensively
- Items still needed are:
 - POREX specs on pore volume percent in order to get pricing quotes for both positive and negative values
 - which structure should be used for grey and white matter target contrast

Profile Revisions (Ms. Matthews)

- A well-organized flow chart will be included in section 3.4.3, which will be a user-friendly feature
- The team will be asked to review the document again prior to release for public comment
- Reviewers are also asked to use "track changes" in Word – Dr. Perlman will collate all edits and clearly highlight recent changes made for reviewer convenience

Nuclear Medicine BC Calls:

- Feb 19: SPECT BC
- Feb 26: Combined NM BCs - TBD

SPECT Task Forces: (Tuesdays at 2 pm CT)

- Feb 16: Phantoms / DRO Group – Drs. Dickson and Zimmerman
 - Feb 23: Clinical / Literature Review – Dr. Seibyl
-